Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiologic and genomewide association studies have linked loss-of-function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. Subsequently, 44 human participants (with triglyceride levels of either 90 to 150 mg per deciliter [1.0 to 1.7 mmol per liter] or >150 mg per deciliter, depending on the dose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose (20, 40, or 80 mg) or multiple doses (10, 20, 40, or 60 mg per week for 6 weeks). The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipids and lipoproteins. RESULTS: The treated mice had dose-dependent reductions in levels of hepatic Angptl3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as reductions in liver triglyceride content and atherosclerosis progression and increases in insulin sensitivity. After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 33.2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein B (3.4 to 25.7%), and apolipoprotein C-III (18.9 to 58.8%). Three participants who received the antisense oligonucleotide and three who received placebo reported dizziness or headache. There were no serious adverse events. CONCLUSIONS: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“A decrease in VLDL-TG secretion, but not in VLDL apoB secretion or VLDL clearance, was observed in mouse models treated with a monoclonal antibody6 or antisense oligonucleotides8 against ANGPTL3.”
In the citing paper
“In initial studies, treatment with Vupanorsen was associated with a 33%–63% decrease in triglycerides as well as reductions in Apo-C III, remnant and total cholesterol, HDL-C, and LDL-C (169).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [169]
In the citing paper
“In a dose-finding study in HTG patients, IONIS-ANGPTL3-LRx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.82”
From Clinical review on triglycerides (2020) · cites this paper as [82]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationWallace, C., Newhouse, S. J., Braund, P., Zhang, F., Tobin, M., Falchi, M., Ahmadi, K., Dobson, R. J., Marçano, A. C. B., Hajat, C., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.11.001 · Cited by 439
Research works printed but not linked: 1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Another approach that is currently being investigated is the inhibition of ANGPTL3 production by antisense oligonucleotides.(345) IONIS-ANGPTL3-LRx, an antisense oligonucleotide targeting ANGPTL3, another critical protein in the clearance of TRLs, reduces plasma TGs by about 85%.”
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“In the healthy group, this ASO could dose-dependently decrease TG by ~30% to 60%.(292) In addition, LDL and HDL were highly positively affected.”
BackgroundRichardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Self-citationSeyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Genetics of blood lipids among ∼300,000 multi-ethnic participants of the Million Veteran Program
Global Lipids Genetics Consortium, Klarin, D., Myocardial Infarction Genetics (MIGen) Consortium, The Geisinger-Regeneron DiscovEHR Collaboration, Program, T. V. M. V., Damrauer, S. M., Cho, K., Sun, Y. V., Teslovich, T. M., Honerlaw, J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0222-9 · Cited by 625
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“82 In a dose-finding study in HTG patients, IONIS-ANGPTL3-L Rx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.”
BackgroundInfluentialRemnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study
Quispe, R., Martin, S. S., Michos, E. D., Lamba, I., Blumenthal, R. S., Saeed, A., Lima, J., Puri, R., Nomura, S., Tsai, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab432 · Cited by 441
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
Qiu, M., Glass, Z., Chen, J., Haas, M., Jin, X., Zhao, X., Rui, X., Ye, Z., Li, Y., Zhang, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020401118 · Cited by 409
Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials
Shi, Y., Zhang, H., Huang, S., Yin, L., Wang, F., Luo, P., & Huang, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01055-2 · Cited by 362
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 331
Antisense technology: A review
Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 326
Self-citationTherapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
A decade of genome-wide association studies for coronary artery disease: the challenges ahead
Erdmann, J., Kessler, T., Munoz Venegas, L., & Schunkert, H. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy084 · Cited by 325
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Hoogeveen, R. C., & Ballantyne, C. M. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa252 · Cited by 307
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
Gaudet, D., Karwatowska-Prokopczuk, E., Baum, S. J., Hurh, E., Kingsbury, J., Bartlett, V. J., Figueroa, A. L., Piscitelli, P., Singleton, W., Witztum, J. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa689 · Cited by 279
Self-citationLipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Long Noncoding RNA Discovery in Cardiovascular Disease: Decoding Form to Function
Sallam, T., Sandhu, J., & Tontonoz, P. (2018) · Circulation Research · doi:10.1161/circresaha.117.311802 · Cited by 254
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
Rosenson, R. S., Gaudet, D., Hegele, R. A., Ballantyne, C. M., Nicholls, S. J., Lucas, K. J., San Martin, J., Zhou, R., Muhsin, M., Chang, T., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404147 · Cited by 249
Genetics of Common, Complex Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2019) · Cell · doi:10.1016/j.cell.2019.02.015 · Cited by 239
Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231
Alexander, V. J., Xia, S., Hurh, E., Hughes, S. G., O’Dea, L., Geary, R. S., Witztum, J. L., & Tsimikas, S. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz209 · Cited by 231
Self-citationAngiopoietin-like 3 in lipoprotein metabolism
Kersten, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.119 · Cited by 220
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
Carbone, C., Piro, G., Merz, V., Simionato, F., Santoro, R., Zecchetto, C., Tortora, G., & Melisi, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020431 · Cited by 200
Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216
Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 210
Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab820 · Cited by 210
Self-citationWadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac822 · Cited by 200
Adam, R. C., Mintah, I. J., Alexa-Braun, C. A., Shihanian, L. M., Lee, J. S., Banerjee, P., Hamon, S. C., Kim, H. I., Cohen, J. C., Hobbs, H. H., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000888 · Cited by 208
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A., & Valenti, L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 202
Wahane, A., Waghmode, A., Kapphahn, A., Dhuri, K., Gupta, A., & Bahal, R. (2020) · Molecules · doi:10.3390/molecules25122866 · Cited by 197
Contribution of remnant cholesterol to cardiovascular risk
Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13059 · Cited by 189
Vallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 174
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Self-citationRegulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Genomic insights into the causes of type 2 diabetes
Langenberg, C., & Lotta, L. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31132-2 · Cited by 149
Chait, A., & Eckel, R. H. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0203 · Cited by 128
Crooke, S. T., Baker, B. F., Xia, S., Yu, R. Z., Viney, N. J., Wang, Y., Tsimikas, S., & Geary, R. S. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0753 · Cited by 127
Self-citationCrooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 134
An oral antisense oligonucleotide for PCSK9 inhibition
Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L., Rosengren, B., Kakol-Palm, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9117 · Cited by 120
Self-citationCui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 143
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114
“Although genetic studies in mice had defined ANGPTL3, 4 and 8 as modulators of LpL activity, establishing the association that humans with hypolipoproteinemia and reduced levels of all ApoB lipoproteins were due to a defect in ANGPTL3 has driven major pharmaceutical interests toward this target.”
BackgroundInfluentialLu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 131
Low-density lipoprotein particles in atherosclerosis
Qiao, Y.-N., Zou, Y., & Guo, S. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.931931 · Cited by 137
New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B
Nurmohamed, N. S., Návar, A. M., & Kastelein, J. J. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.079 · Cited by 127
Reeskamp, L. F., Millar, J. S., Wu, L., Jansen, H., van Harskamp, D., Schierbeek, H., Gipe, D. A., Rader, D. J., Dallinga-Thie, G. M., Hovingh, G. K., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315204 · Cited by 109
Xu, Y.-X., Redon, V., Yu, H., Querbes, W., Pirruccello, J., Liebow, A., Deik, A., Trindade, K., Wang, X., Musunuru, K., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.031 · Cited by 105
Severe insulin resistance syndromes
Angelidi, A. M., Filippaios, A., & Mantzoros, C. S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142245 · Cited by 125
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Brandts, J., & Ray, K. K. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00860-8 · Cited by 119
Watts, G. F., Schwabe, C., Scott, R., Gladding, P. A., Sullivan, D., Baker, J., Clifton, P., Hamilton, J., Given, B., Melquist, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02494-2 · Cited by 105
Antisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 115
Self-citationApolipoprotein C-III in triglyceride-rich lipoprotein metabolism
Ramms, B., & Gordts, P. L. S. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000502 · Cited by 101
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 99
Self-citationWang, Y., Yu, R. Z., Henry, S., & Geary, R. S. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1621838 · Cited by 95
Self-citationTargeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 100
Viney, N. J., Guo, S., Tai, L.-J., Baker, B. F., Aghajan, M., Jung, S. W., Yu, R. Z., Booten, S., Murray, H., Machemer, T., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13154 · Cited by 96
Self-citationThe Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia
Hu, B., Li, B., Li, K., Liu, Y., Li, C., Zheng, L., Zhang, M., Yang, T., Guo, S., Dong, X., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1418 · Cited by 92
New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk
Kersten, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000600 · Cited by 94
A new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 94
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DeGraaf, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 92
Wang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89
Emdin, C. A., Khera, A. V., Chaffin, M., Klarin, D., Natarajan, P., Aragam, K., Haas, M., Bick, A., Zekavat, S. M., Nomura, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03911-8 · Cited by 95
RNA Therapeutics in Cardiovascular Precision Medicine
Laina, A., Gatsiou, A., Georgiopoulos, G., Stamatelopoulos, K., & Stellos, K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00953 · Cited by 88
Kersten, S. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000789 · Cited by 83
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 80
Glicksberg, B. S., Johnson, K. W., & Dudley, J. T. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy114 · Cited by 83
Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 82
Gait, M. J., Arzumanov, A. A., McClorey, G., Godfrey, C., Betts, C., Hammond, S. M., & Wood, M. J. A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0747 · Cited by 83
Ginsberg, H. N., & Goldberg, I. J. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 80
Ray, K. K., Oru, E., Rosenson, R. S., Jones, J., Ma, X., Walgren, J., Haupt, A., Verma, S., Gaudet, D., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00507-0 · Cited by 81
“13,14 The first RNA-based therapy to target ANGPTL3 was the antisense oligonucleotide vupanorsen.”
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Chen, P., Gao, W.-Y., Liou, J.-W., Lin, C.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147310 · Cited by 84
Brandts, J., & Ray, K. K. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.004 · Cited by 93
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 104
Lotta, L. A., Stewart, I. D., Sharp, S. J., Day, F. R., Burgess, S., Luan, J., Bowker, N., Cai, L., Li, C., Wittemans, L. B. L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2866 · Cited by 72
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
Gaudet, D., Greber‐Platzer, S., Reeskamp, L. F., Iannuzzo, G., Rosenson, R. S., Saheb, S., Stefanutti, C., Stroes, E. S. G., Wiegman, A., Turner, T. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae325 · Cited by 92
Advancing targeted protein degradation for metabolic diseases therapy
Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 78
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Triglyceride-rich lipoproteins and cardiovascular diseases
Xu, D., Xie, L., Cheng, C., Xue, F., & Sun, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1409653 · Cited by 73
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Skeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 83
Generoso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000468 · Cited by 69
Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments
Wolf, M., & Hunziker, P. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09961-y · Cited by 77
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 81
Metadata
- Authors
- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S., Witztum, J. L., Crooke, R. M., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618984243
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 48 · 2023: 51 · 2022: 85 · 2021: 86 · 2020: 90 · 2019: 59 · 2018: 72 · 2017: 26
- FWCI
- 52.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, antisense oligonucleotides, triglyceride lowering, hypertriglyceridemia, LDL cholesterol, hepatic triglyceride content, atherosclerosis, insulin sensitivity, lipoproteins, apolipoprotein B, apolipoprotein C-III, loss-of-function mutations, pharmacokinetics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Aged, Animals, Coronary Artery Disease, Disease Models, Animal, Double-Blind Method, Female, Humans, Lipids, Male, Mice, Inbred Strains, Middle Aged, Oligonucleotides, RNA, Messenger, Oligonucleotides, Antisense, Angiopoietins, Dyslipidemias, Atherosclerosis, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.